Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neural Therapeutics Inc. ( (TSE:NURL) ) has provided an announcement.
Neural Therapeutics Inc. announced the approval of 2,720,000 restricted share units and 725,000 stock options by its Board of Directors. These grants, aimed at directors, consultants, and certain officers, are part of the company’s strategy to incentivize its team as it continues to develop innovative treatments for mental health issues related to substance use disorders. The immediate vesting of these shares and options reflects the company’s commitment to advancing its business operations and strengthening its position in the ethnobotanical drug discovery industry.
More about Neural Therapeutics Inc.
Neural Therapeutics Inc. is a leader in ethnobotanical drug discovery, focusing on developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The company utilizes sub-hallucinogenic doses of mescaline extract to enhance safety and scalability while maintaining therapeutic efficacy.
Average Trading Volume: 84,265
See more data about NURL stock on TipRanks’ Stock Analysis page.